Bradley Canino
Stock Analyst at Stifel
(1.71)
# 2,749
Out of 5,090 analysts
89
Total ratings
36.25%
Success rate
-0.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $16.51 | +130.16% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $20.32 | +116.54% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.67 | +461.80% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.42 | +5.63% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $10.59 | +79.41% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $7.68 | +199.48% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $12.79 | +298.75% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $11.95 | +59.00% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $105.63 | -60.24% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $18.31 | +118.46% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $109.60 | +23.18% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $11.00 | +81.82% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.22 | +136.97% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.39 | +619.42% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $96.14 | +2.97% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.67 | +424.34% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $66.62 | -17.44% | 4 | Feb 23, 2024 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $16.51
Upside: +130.16%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $20.32
Upside: +116.54%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.67
Upside: +461.80%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.42
Upside: +5.63%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $10.59
Upside: +79.41%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $7.68
Upside: +199.48%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $12.79
Upside: +298.75%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $11.95
Upside: +59.00%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $105.63
Upside: -60.24%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.31
Upside: +118.46%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $109.60
Upside: +23.18%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $11.00
Upside: +81.82%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $4.22
Upside: +136.97%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.39
Upside: +619.42%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $96.14
Upside: +2.97%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.67
Upside: +424.34%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $66.62
Upside: -17.44%